img

Global Plasma-derived Therapies Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends

Publisher : MRA | Format : PDF

Global Plasma-derived Therapies Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Plasma-derived therapeutics start from human blood plasma instead of the chemical or synthetic materials from which most pharmaceuticals are made.
Due to the COVID-19 pandemic, the global Plasma-derived Therapies market size was US$ million in 2023 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the forecast period 2023-2033. Fully considering the economic change by this health crisis, Albumin accounting for % of the Plasma-derived Therapies global market in 2023, is projected to value US$ million by 2033, growing at a revised % CAGR from 2023 to 2033. While Hemophilia segment is altered to an % CAGR throughout this forecast period.
The global key companies of Plasma-derived Therapies include CSL Behring LLC, Shire, Bayer, Kedrion, Takeda, Biotest, Octaparma, Bio Products Laboratory (BPL) and LFB, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
The United States Plasma-derived Therapies market size was US$ million in 2023, while China size was US$ million. The proportion of the United States was % in 2023, while China percentage was %, and it is predicted that China share will reach % in 2033, trailing a CAGR of % through the analysis period. As for the Europe Plasma-derived Therapies landscape, Germany is projected to reach US$ million by 2033. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Plasma-derived Therapies market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Plasma-derived Therapies market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Plasma-derived Therapies market. Readers of the report can become informed about current and future trends of the global Plasma-derived Therapies market and how they will impact market growth during the forecast period.



By Company


CSL Behring LLC
Shire
Bayer
Kedrion
Takeda
Biotest
Octaparma
Bio Products Laboratory (BPL)
LFB
Grifols
Segment by Type
Albumin
Immunoglobulin
Factor VIII
Others

Segment by Application


Hemophilia
Primary Immunodeficiencies (PIDs)
Idiopathic Thrombocytopenic Purpura (ITP)
COVID-19
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Plasma-derived Therapies in global and regional level.
Chapter 3Detailed analysis of Plasma-derived Therapies companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Plasma-derived Therapies revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Plasma-derived Therapies Market Size Growth Rate by Type: 2018 VS 2023 VS 2033
1.2.2 Albumin
1.2.3 Immunoglobulin
1.2.4 Factor VIII
1.2.5 Others
1.3 Market by Application
1.3.1 Global Plasma-derived Therapies Market Growth Rate by Application: 2018 VS 2023 VS 2033
1.3.2 Hemophilia
1.3.3 Primary Immunodeficiencies (PIDs)
1.3.4 Idiopathic Thrombocytopenic Purpura (ITP)
1.3.5 COVID-19
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Plasma-derived Therapies Market Size (2018-2033)
2.2 Plasma-derived Therapies Market Size across Key Geographies Worldwide: 2018 VS 2023 VS 2033
2.3 Global Plasma-derived Therapies Market Size by Region (2018-2023)
2.4 Global Plasma-derived Therapies Market Size Forecast by Region (2024-2033)
2.5 Global Top 10 Plasma-derived Therapies Countries Ranking by Market Size
3 Plasma-derived Therapies Competitive by Company
3.1 Global Plasma-derived Therapies Revenue by Players
3.1.1 Global Plasma-derived Therapies Revenue by Players (2018-2023)
3.1.2 Global Plasma-derived Therapies Market Share by Players (2018-2023)
3.2 Global Plasma-derived Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Plasma-derived Therapies Revenue
3.4 Global Plasma-derived Therapies Market Concentration Ratio
3.4.1 Global Plasma-derived Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Plasma-derived Therapies Revenue in 2023
3.5 Global Key Players of Plasma-derived Therapies Head office and Area Served
3.6 Global Key Players of Plasma-derived Therapies, Product and Application
3.7 Global Key Players of Plasma-derived Therapies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Plasma-derived Therapies Breakdown Data by Type
4.1 Global Plasma-derived Therapies Historic Revenue by Type (2018-2023)
4.2 Global Plasma-derived Therapies Forecasted Revenue by Type (2024-2033)
5 Global Plasma-derived Therapies Breakdown Data by Application
5.1 Global Plasma-derived Therapies Historic Market Size by Application (2018-2023)
5.2 Global Plasma-derived Therapies Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Plasma-derived Therapies Revenue by Company (2021-2023)
6.2 North America Plasma-derived Therapies Revenue by Type (2018-2033)
6.3 North America Plasma-derived Therapies Revenue by Application (2018-2033)
6.4 North America Plasma-derived Therapies Revenue by Country (2018-2033)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Plasma-derived Therapies Revenue by Company (2021-2023)
7.2 Europe Plasma-derived Therapies Revenue by Type (2018-2033)
7.3 Europe Plasma-derived Therapies Revenue by Application (2018-2033)
7.4 Europe Plasma-derived Therapies Revenue by Country (2018-2033)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Plasma-derived Therapies Revenue by Company (2021-2023)
8.2 Asia Pacific Plasma-derived Therapies Revenue by Type (2018-2033)
8.3 Asia Pacific Plasma-derived Therapies Revenue by Application (2018-2033)
8.4 Asia Pacific Plasma-derived Therapies Revenue by Region (2018-2033)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Plasma-derived Therapies Revenue by Company (2021-2023)
9.2 Latin America Plasma-derived Therapies Revenue by Type (2018-2033)
9.3 Latin America Plasma-derived Therapies Revenue by Application (2018-2033)
9.4 Latin America Plasma-derived Therapies Revenue by Country (2018-2033)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Plasma-derived Therapies Revenue by Company (2021-2023)
10.2 Middle East and Africa Plasma-derived Therapies Revenue by Type (2018-2033)
10.3 Middle East and Africa Plasma-derived Therapies Revenue by Application (2018-2033)
10.4 Middle East and Africa Plasma-derived Therapies Revenue by Country (2018-2033)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 CSL Behring LLC
11.1.1 CSL Behring LLC Company Details
11.1.2 CSL Behring LLC Business Overview
11.1.3 CSL Behring LLC Plasma-derived Therapies Products and Services
11.1.4 CSL Behring LLC Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023)
11.1.5 CSL Behring LLC Plasma-derived Therapies SWOT Analysis
11.1.6 CSL Behring LLC Recent Development
11.2 Shire
11.2.1 Shire Company Details
11.2.2 Shire Business Overview
11.2.3 Shire Plasma-derived Therapies Products and Services
11.2.4 Shire Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023)
11.2.5 Shire Plasma-derived Therapies SWOT Analysis
11.2.6 Shire Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Plasma-derived Therapies Products and Services
11.3.4 Bayer Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023)
11.3.5 Bayer Plasma-derived Therapies SWOT Analysis
11.3.6 Bayer Recent Development
11.4 Kedrion
11.4.1 Kedrion Company Details
11.4.2 Kedrion Business Overview
11.4.3 Kedrion Plasma-derived Therapies Products and Services
11.4.4 Kedrion Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023)
11.4.5 Kedrion Plasma-derived Therapies SWOT Analysis
11.4.6 Kedrion Recent Development
11.5 Takeda
11.5.1 Takeda Company Details
11.5.2 Takeda Business Overview
11.5.3 Takeda Plasma-derived Therapies Products and Services
11.5.4 Takeda Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023)
11.5.5 Takeda Plasma-derived Therapies SWOT Analysis
11.5.6 Takeda Recent Development
11.6 Biotest
11.6.1 Biotest Company Details
11.6.2 Biotest Business Overview
11.6.3 Biotest Plasma-derived Therapies Products and Services
11.6.4 Biotest Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023)
11.6.5 Biotest Plasma-derived Therapies SWOT Analysis
11.6.6 Biotest Recent Development
11.7 Octaparma
11.7.1 Octaparma Company Details
11.7.2 Octaparma Business Overview
11.7.3 Octaparma Plasma-derived Therapies Products and Services
11.7.4 Octaparma Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023)
11.7.5 Octaparma Plasma-derived Therapies SWOT Analysis
11.7.6 Octaparma Recent Development
11.8 Bio Products Laboratory (BPL)
11.8.1 Bio Products Laboratory (BPL) Company Details
11.8.2 Bio Products Laboratory (BPL) Business Overview
11.8.3 Bio Products Laboratory (BPL) Plasma-derived Therapies Products and Services
11.8.4 Bio Products Laboratory (BPL) Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023)
11.8.5 Bio Products Laboratory (BPL) Plasma-derived Therapies SWOT Analysis
11.8.6 Bio Products Laboratory (BPL) Recent Development
11.9 LFB
11.9.1 LFB Company Details
11.9.2 LFB Business Overview
11.9.3 LFB Plasma-derived Therapies Products and Services
11.9.4 LFB Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023)
11.9.5 LFB Plasma-derived Therapies SWOT Analysis
11.9.6 LFB Recent Development
11.10 Grifols
11.10.1 Grifols Company Details
11.10.2 Grifols Business Overview
11.10.3 Grifols Plasma-derived Therapies Products and Services
11.10.4 Grifols Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023)
11.10.5 Grifols Plasma-derived Therapies SWOT Analysis
11.10.6 Grifols Recent Development
12 Plasma-derived Therapies Market Dynamics
12.1 Plasma-derived Therapies Industry Trends
12.2 Plasma-derived Therapies Market Drivers
12.3 Plasma-derived Therapies Market Challenges
12.4 Plasma-derived Therapies Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Plasma-derived Therapies Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2023 VS 2033
Table 2. Key Players of Albumin
Table 3. Key Players of Immunoglobulin
Table 4. Key Players of Factor VIII
Table 5. Key Players of Others
Table 6. Global Plasma-derived Therapies Market Size Growth Rate by Application (US$ Million), 2018 VS 2023 VS 2033
Table 7. Global Plasma-derived Therapies Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2023 VS 2033
Table 8. Global Plasma-derived Therapies Revenue by Region (2018-2023) & (US$ Million)
Table 9. Global Plasma-derived Therapies Revenue Forecast by Region (2024-2033) & (US$ Million)
Table 10. Global Plasma-derived Therapies Market Size of Top 10 Countries, 2018 VS 2023 VS 2033, (US$ Million)
Table 11. Global Plasma-derived Therapies Revenue by Players (2018-2023) & (US$ Million)
Table 12. Global Plasma-derived Therapies Market Share by Players (2018-2023)
Table 13. Global Top Plasma-derived Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Plasma-derived Therapies as of 2023)
Table 14. Ranking of Global Top Plasma-derived Therapies Companies by Revenue (US$ Million) in 2023
Table 15. Global 5 Largest Players Market Share by Plasma-derived Therapies Revenue (CR5 and HHI) & (2018-2023)
Table 16. Global Key Players of Plasma-derived Therapies, Headquarters and Area Served
Table 17. Global Key Players of Plasma-derived Therapies, Product and Application
Table 18. Global Key Players of Plasma-derived Therapies, Date of Enter into This Industry
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Plasma-derived Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 21. Global Plasma-derived Therapies Revenue Market Share by Type (2018-2023)
Table 22. Global Plasma-derived Therapies Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 23. Global Plasma-derived Therapies Revenue Market Share by Type (2024-2033)
Table 24. Global Plasma-derived Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 25. Global Plasma-derived Therapies Revenue Market Share by Application (2018-2023)
Table 26. Global Plasma-derived Therapies Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 27. Global Plasma-derived Therapies Revenue Market Share by Application (2024-2033)
Table 28. North America Plasma-derived Therapies Revenue by Company (2021-2023) & (US$ Million)
Table 29. North America Plasma-derived Therapies Revenue by Type (2018-2023) & (US$ Million)
Table 30. North America Plasma-derived Therapies Revenue by Type (2024-2033) & (US$ Million)
Table 31. North America Plasma-derived Therapies Revenue by Application (2018-2023) & (US$ Million)
Table 32. North America Plasma-derived Therapies Revenue by Application (2024-2033) & (US$ Million)
Table 33. North America Plasma-derived Therapies Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 34. North America Plasma-derived Therapies Revenue by Country (2018-2023) & (US$ Million)
Table 35. North America Plasma-derived Therapies Revenue by Country (2024-2033) & (US$ Million)
Table 36. Europe Plasma-derived Therapies Revenue by Company (2021-2023) & (US$ Million)
Table 37. Europe Plasma-derived Therapies Revenue by Type (2018-2023) & (US$ Million)
Table 38. Europe Plasma-derived Therapies Revenue by Type (2024-2033) & (US$ Million)
Table 39. Europe Plasma-derived Therapies Revenue by Application (2018-2023) & (US$ Million)
Table 40. Europe Plasma-derived Therapies Revenue by Application (2024-2033) & (US$ Million)
Table 41. Europe Plasma-derived Therapies Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 42. Europe Plasma-derived Therapies Revenue by Country (2018-2023) & (US$ Million)
Table 43. Europe Plasma-derived Therapies Revenue by Country (2024-2033) & (US$ Million)
Table 44. Asia Pacific Plasma-derived Therapies Revenue by Company (2021-2023) & (US$ Million)
Table 45. Asia Pacific Plasma-derived Therapies Revenue by Type (2018-2023) & (US$ Million)
Table 46. Asia Pacific Plasma-derived Therapies Revenue by Type (2024-2033) & (US$ Million)
Table 47. Asia Pacific Plasma-derived Therapies Revenue by Application (2018-2023) & (US$ Million)
Table 48. Asia Pacific Plasma-derived Therapies Revenue by Application (2024-2033) & (US$ Million)
Table 49. Asia-Pacific Plasma-derived Therapies Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 50. Asia Pacific Plasma-derived Therapies Revenue by Region (2018-2023) & (US$ Million)
Table 51. Asia Pacific Plasma-derived Therapies Revenue by Region (2024-2033) & (US$ Million)
Table 52. Latin America Plasma-derived Therapies Revenue by Company (2021-2023) & (US$ Million)
Table 53. Latin America Plasma-derived Therapies Revenue by Type (2018-2023) & (US$ Million)
Table 54. Latin America Plasma-derived Therapies Revenue by Type (2024-2033) & (US$ Million)
Table 55. Latin America Plasma-derived Therapies Revenue by Application (2018-2023) & (US$ Million)
Table 56. Latin America Plasma-derived Therapies Revenue by Application (2024-2033) & (US$ Million)
Table 57. Latin America Plasma-derived Therapies Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 58. Latin America Plasma-derived Therapies Revenue by Country (2018-2023) & (US$ Million)
Table 59. Latin America Plasma-derived Therapies Revenue by Country (2024-2033) & (US$ Million)
Table 60. Middle East and Africa Plasma-derived Therapies Revenue by Company (2021-2023) & (US$ Million)
Table 61. Middle East and Africa Plasma-derived Therapies Revenue by Type (2018-2023) & (US$ Million)
Table 62. Middle East and Africa Plasma-derived Therapies Revenue by Type (2024-2033) & (US$ Million)
Table 63. Middle East and Africa Plasma-derived Therapies Revenue by Application (2018-2023) & (US$ Million)
Table 64. Middle East and Africa Plasma-derived Therapies Revenue by Application (2024-2033) & (US$ Million)
Table 65. Middle East and Africa Plasma-derived Therapies Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 66. Middle East and Africa Plasma-derived Therapies Revenue by Country (2018-2023) & (US$ Million)
Table 67. Middle East and Africa Plasma-derived Therapies Revenue by Country (2024-2033) & (US$ Million)
Table 68. CSL Behring LLC Company Details
Table 69. CSL Behring LLC Business Overview
Table 70. CSL Behring LLC Plasma-derived Therapies Product and Services
Table 71. CSL Behring LLC Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023) & (US$ Million)
Table 72. CSL Behring LLC Plasma-derived Therapies SWOT Analysis
Table 73. CSL Behring LLC Recent Development
Table 74. Shire Company Details
Table 75. Shire Business Overview
Table 76. Shire Plasma-derived Therapies Product and Services
Table 77. Shire Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023) & (US$ Million)
Table 78. Shire Plasma-derived Therapies SWOT Analysis
Table 79. Shire Recent Development
Table 80. Bayer Company Details
Table 81. Bayer Business Overview
Table 82. Bayer Plasma-derived Therapies Product and Services
Table 83. Bayer Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023) & (US$ Million)
Table 84. Bayer Plasma-derived Therapies SWOT Analysis
Table 85. Bayer Recent Development
Table 86. Kedrion Company Details
Table 87. Kedrion Business Overview
Table 88. Kedrion Plasma-derived Therapies Product and Services
Table 89. Kedrion Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023) & (US$ Million)
Table 90. Kedrion Plasma-derived Therapies SWOT Analysis
Table 91. Kedrion Recent Development
Table 92. Takeda Company Details
Table 93. Takeda Business Overview
Table 94. Takeda Plasma-derived Therapies Product and Services
Table 95. Takeda Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023) & (US$ Million)
Table 96. Takeda Plasma-derived Therapies SWOT Analysis
Table 97. Takeda Recent Development
Table 98. Biotest Company Details
Table 99. Biotest Business Overview
Table 100. Biotest Plasma-derived Therapies Product and Services
Table 101. Biotest Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023) & (US$ Million)
Table 102. Biotest Plasma-derived Therapies SWOT Analysis
Table 103. Biotest Recent Development
Table 104. Octaparma Company Details
Table 105. Octaparma Business Overview
Table 106. Octaparma Plasma-derived Therapies Product and Services
Table 107. Octaparma Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023) & (US$ Million)
Table 108. Octaparma Plasma-derived Therapies SWOT Analysis
Table 109. Octaparma Recent Development
Table 110. Bio Products Laboratory (BPL) Company Details
Table 111. Bio Products Laboratory (BPL) Business Overview
Table 112. Bio Products Laboratory (BPL) Plasma-derived Therapies Product and Services
Table 113. Bio Products Laboratory (BPL) Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023) & (US$ Million)
Table 114. Bio Products Laboratory (BPL) Plasma-derived Therapies SWOT Analysis
Table 115. Bio Products Laboratory (BPL) Recent Development
Table 116. LFB Company Details
Table 117. LFB Business Overview
Table 118. LFB Plasma-derived Therapies Product and Services
Table 119. LFB Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023) & (US$ Million)
Table 120. LFB Plasma-derived Therapies SWOT Analysis
Table 121. LFB Recent Development
Table 122. Grifols Company Details
Table 123. Grifols Business Overview
Table 124. Grifols Plasma-derived Therapies Product and Services
Table 125. Grifols Plasma-derived Therapies Revenue in Plasma-derived Therapies Business (2018-2023) & (US$ Million)
Table 126. Grifols Plasma-derived Therapies SWOT Analysis
Table 127. Grifols Recent Development
Table 128. Plasma-derived Therapies Market Trends
Table 129. Plasma-derived Therapies Market Drivers
Table 130. Plasma-derived Therapies Market Challenges
Table 131. Plasma-derived Therapies Market Restraints
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Plasma-derived Therapies Product Picture
Figure 2. Global Plasma-derived Therapies Market Size by Type (US$ Million): 2018 VS 2023 VS 2033
Figure 3. Global Plasma-derived Therapies Market Share by Type: 2023 VS 2033
Figure 4. Albumin Features
Figure 5. Immunoglobulin Features
Figure 6. Factor VIII Features
Figure 7. Others Features
Figure 8. Global Plasma-derived Therapies Market Size by Application (US$ Million): 2018 VS 2023 VS 2033
Figure 9. Global Plasma-derived Therapies Market Share by Application: 2023 VS 2033
Figure 10. Hemophilia
Figure 11. Primary Immunodeficiencies (PIDs)
Figure 12. Idiopathic Thrombocytopenic Purpura (ITP)
Figure 13. COVID-19
Figure 14. Others
Figure 15. Plasma-derived Therapies Report Years Considered
Figure 16. Global Plasma-derived Therapies Revenue, (US$ Million), 2018 VS 2023 VS 2033
Figure 17. Global Plasma-derived Therapies Market Size 2018-2033 (US$ Million)
Figure 18. Global Plasma-derived Therapies Market Size Market Share by Region: 2023 VS 2033
Figure 19. Global Plasma-derived Therapies Revenue Market Share by Region in 2018 VS 2023
Figure 20. Global Plasma-derived Therapies Revenue Market Share Forecast by Region (2024-2033)
Figure 21. Global Top 10 Plasma-derived Therapies Countries Ranking by Market Size (US$ Million) in 2023
Figure 22. Global Plasma-derived Therapies Market Size of Top 10 Countries, 2018 VS 2023 VS 2033, (US$ Million)
Figure 23. Global Plasma-derived Therapies Market Share by Players in 2023
Figure 24. Global Top Plasma-derived Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Plasma-derived Therapies as of 2023)
Figure 25. The Top 10 and 5 Players Market Share by Plasma-derived Therapies Revenue in 2023
Figure 26. North America Plasma-derived Therapies Revenue Market Share by Company in 2023
Figure 27. North America Plasma-derived Therapies Revenue Market Share by Type (2018-2033)
Figure 28. North America Plasma-derived Therapies Revenue Market Share by Application (2018-2033)
Figure 29. North America Plasma-derived Therapies Revenue Share by Country (2018-2033)
Figure 30. United States Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 31. Canada Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 32. Europe Plasma-derived Therapies Revenue Market Share by Company in 2023
Figure 33. Europe Plasma-derived Therapies Revenue Market Share by Type (2018-2033)
Figure 34. Europe Plasma-derived Therapies Revenue Market Share by Application (2018-2033)
Figure 35. Europe Plasma-derived Therapies Revenue Share by Country (2018-2033)
Figure 36. Germany Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 37. France Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 38. U.K. Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 39. Italy Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 40. Russia Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 41. Asia Pacific Plasma-derived Therapies Revenue Market Share by Company in 2023
Figure 42. Asia Pacific Plasma-derived Therapies Revenue Market Share by Type (2018-2033)
Figure 43. Asia Pacific Plasma-derived Therapies Revenue Market Share by Application (2018-2033)
Figure 44. Asia Pacific Plasma-derived Therapies Revenue Share by Region (2018-2033)
Figure 45. China Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 46. Japan Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 47. South Korea Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 48. India Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 49. Australia Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 50. China Taiwan Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 51. Indonesia Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 52. Thailand Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 53. Malaysia Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 54. Latin America Plasma-derived Therapies Revenue Market Share by Company in 2023
Figure 55. Latin America Plasma-derived Therapies Revenue Market Share by Type (2018-2033)
Figure 56. Latin America Plasma-derived Therapies Revenue Market Share by Application (2018-2033)
Figure 57. Latin America Plasma-derived Therapies Revenue Share by Country (2018-2033)
Figure 58. Mexico Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 59. Brazil Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 60. Argentina Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 61. Middle East and Africa Plasma-derived Therapies Revenue Market Share by Company in 2023
Figure 62. Middle East and Africa Plasma-derived Therapies Revenue Market Share by Type (2018-2033)
Figure 63. Middle East and Africa Plasma-derived Therapies Revenue Market Share by Application (2018-2033)
Figure 64. Middle East and Africa Plasma-derived Therapies Revenue Share by Country (2018-2033)
Figure 65. Turkey Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 66. Saudi Arabia Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 67. UAE Plasma-derived Therapies Revenue (2018-2033) & (US$ Million)
Figure 68. CSL Behring LLC Revenue Growth Rate in Plasma-derived Therapies Business (2018-2023)
Figure 69. Shire Revenue Growth Rate in Plasma-derived Therapies Business (2018-2023)
Figure 70. Bayer Revenue Growth Rate in Plasma-derived Therapies Business (2018-2023)
Figure 71. Kedrion Revenue Growth Rate in Plasma-derived Therapies Business (2018-2023)
Figure 72. Takeda Revenue Growth Rate in Plasma-derived Therapies Business (2018-2023)
Figure 73. Biotest Revenue Growth Rate in Plasma-derived Therapies Business (2018-2023)
Figure 74. Octaparma Revenue Growth Rate in Plasma-derived Therapies Business (2018-2023)
Figure 75. Bio Products Laboratory (BPL) Revenue Growth Rate in Plasma-derived Therapies Business (2018-2023)
Figure 76. LFB Revenue Growth Rate in Plasma-derived Therapies Business (2018-2023)
Figure 77. Grifols Revenue Growth Rate in Plasma-derived Therapies Business (2018-2023)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed